**EML4-ALK** Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi P. Koivunen, Craig Merrel, Kreshnik Zejnullahu, Carly Murphy, Eugene Lifshits, Alison J. Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Roman Thomas, Jinseon Lee, William G. Richards, David J. Sugarbaker, Christopher Ducko, Neal Lindeman, Matthew Meyerson, and Pasi A. Janne

**Abstract**

**Purpose:** The *EML4-ALK* fusion gene has been detected in ~7% of Japanese non-small cell lung cancers (NSCLC). We determined the frequency of *EML4-ALK* in Caucasian NSCLC and in NSCLC cell lines. We also determined whether TAE684, a specific ALK inhibitor, would inhibit the growth of *EML4-ALK*-containing cell lines in vitro and in vivo.

**Experimental Design:** We screened 305 primary NSCLC (both U.S. (*n* = 138) and Korean (*n* = 167) patients) and 83 NSCLC cell lines using reverse transcription-PCR by exon array analyses. We evaluated the efficacy of TAE684 against NSCLC cell lines in vitro and in vivo.

**Results:** We detected four different variants, including two novel variants, of *EML4-ALK* using reverse transcription-PCR in 8 of 305 tumors (3%) and 3 of 83 (3.6%) NSCLC cell lines. All *EML4-ALK*-containing tumors and cell lines were adenocarcinomas. *EML4-ALK* was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers (6% versus 1%; *P* = 0.049). TAE684 inhibited the growth of one of three (H3122) *EML4-ALK*-containing cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis. In another *EML4-ALK* cell line, DFCI032, TAE684 was ineffective due to coactivation of epidermal growth factor receptor and ERBB2. The combination of TAE684 and CL-387,785 (epidermal growth factor receptor/ERBB2 kinase inhibitor) inhibited growth and Akt phosphorylation and led to apoptosis in the DFCI032 cell line.

**Conclusions:** *EML4-ALK* is found in the minority of NSCLC. ALK kinase inhibitors alone or in combination may nevertheless be clinically effective treatments for NSCLC patients whose tumors contain *EML4-ALK*.

**Anaplastic lymphoma kinase (ALK)** kinase was originally discovered from chromosomal translocations leading to the production of fusion proteins consisting of the COOH-terminal kinase domain of ALK and the NH2-terminal portions of different genes (1). Translocations of ALK have been identified in 40% to 60% of anaplastic lymphomas and in B-cell lymphomas, neuroblastomas, and myofibroblastic tumors (2). *NPM* is the most common fusion partner of ALK (80% of translocations), but at least six other fusion partners have been identified (2). In these fusion proteins, the NH2-terminal portion is responsible for protein oligomerization, which leads to constitutive activation of ALK kinase, and results in aberrant activation of downstream signaling targets including Akt, STAT3, and extracellular signal-regulated kinase 1/2 (ERK1/2; ref. 2).

The fusion of the ALK gene with echinoderm microtubule-associated protein-like 4 (*EML4*) has recently been detected in 6.7% (5 of 75) of Japanese non-small cell lung cancers (NSCLC; ref. 3). ALK and *EML4* are both located in the short arm of chromosome 2 separated by 12 Mb and are oriented in opposite 5’ to 3’ directions. Two different variants of *EML4-ALK* fusion gene have been characterized both involving exons...
20 to 29 of ALK fused to exons 1 to 13 (variant 1) or exons 1 to 20 (variant 2) of EML4. Both variants of the EML4-ALK fusion gene were transforming in 3T3 cells and in Ba/F3 models (3).

Inhibitors of ALK kinase have been developed and examined in preclinical models. Proof-of-concept studies using short hairpin RNA knockdown of ALK in NPM-ALK-containing models led to growth inhibition and apoptosis and suggested that ALK inhibition may be a potentially effective therapeutic strategy (4). This has led to the development and testing of small-molecule inhibitors of ALK. Initial studies have been done using less potent ALK inhibitors such as WHI-P154 (IC50 = 5 μmol/L), pyridones (IC50 for staurosporine, 0.15-0.78 μmol/L), or HSP90 inhibitors (5). Subsequently, more potent and specific ALK inhibitors such as diaminopyrimidines or aminopyrimidines have been developed including TAE684 and PF02341066 (6–8). Both of these inhibitors have good bioavailability and inhibit ALK kinase activity and growth of NPM-ALK-positive lymphoma cells in the low nanomolar range (6–8). PF02341066 is an inhibitor of both MET and ALK presently in phase I clinical development. TAE684 is not currently under clinical development. Neither agent has been examined previously against EML4-ALK.

In the current study, we analyzed the frequency of the EML4-ALK fusion gene in NSCLC cell lines and tumors derived from U.S. and Korean NSCLC patients. In addition, we examined the efficacy of an ALK kinase inhibitor, TAE684, in NSCLC cell lines harboring the EML4-ALK inversion to determine if this would be a potentially effective therapeutic strategy for NSCLC patients whose tumors contain the EML4-ALK inversion (6).

**Materials and Methods**

**Cell lines and tumors.** NSCLC (n = 81) and mesothelioma (n = 2) cell lines were purchased from the American Type Culture Collection or were kind gifts from Drs. John D. Minna and Adi F. Gazdar (University of Texas Southwestern; Supplementary Table S1). DFCI032 and DFCI032 were established at Dana-Farber Cancer Institute from pleural effusions of treatment naive female NSCLC patients. The PC-9, A549, H3122, and H2228 cells were cultured in RPMI 1640 (Sigma) supplemented with 10% fetal bovine serum, 100 units/ml streptomycin, and 1 mmol/L sodium pyruvate. The DFCI032 cells were cultured in ACL-4 medium (Invitrogen) supplemented with 5% fetal bovine serum, 100 units/ml streptomycin, and 1 mmol/L sodium pyruvate.

NSCLC tumors (n = 305) were collected from surgical resections from patients with stages I to III NSCLC when sufficient material for RNA extraction was available. The majority of the specimens (n = 167) were collected at the Samsung Medical Center. Frozen tumor tissues were collected from 809 of 2,442 patients who underwent curative resections or who had not been subjected to mediastinal lymph node dissections. Each of the microdissected tumor specimens stained with H&E was used to confirm the cellular composition of adjacent samples. All specimens underwent pathologic review by two pathologists. One hundred nine tumors obtained during the same period were excluded because they did not meet one or more of the eligibility criteria. Tissue samples were homogenized in TriZol (Life Technologies) and RNA was extracted and purified by using the RNeasy column purification kit (Qiagen). Denaturing formaldehyde gel electrophoresis followed by Northern blotting using a β-actin probe assessed RNA integrity. Samples were excluded if β-actin was not full-length. All patients provided written informed consent.

Cell line specimens were snap frozen and stored at -80°C. RNA was extracted from tumors and cell lines using Trizol (Invitrogen), purified with RNeasy Mini Kit (Qiagen), and used for cDNA synthesis using the QuantiTect reverse transcription kit (Qiagen).

**Exon array studies.** To screen for ALK translocations, we used Affymetrix HuEx-1.0 Exon Array (Affymetrix) data that was generated previously from these cell lines. The HuEx-1.0 array was designed to contain probes mapping to every known and predicted exon in the human genome. We reasoned that translocations in the ALK gene would result in disparate levels of expression between exons 5 and 3’ of the breakpoint, with the expression higher in the 5’ end (kinase domain). After performing array normalization and background correction for all probes, we restricted our analysis to the 104 probes uniquely mapping to the ALK gene (RefSeq NM_004304). To correct for differences in probe response characteristics across the gene, for every sample, we divided each probe intensity value by the average probe intensity across the other wild-type specimens. For each cell line, we computed the location of the most likely breakpoint as the probe that gives the maximum deviation between average expression of 5’ and 3’ probe subsets. Significance levels for each inferred breakpoint were computed using a simple two-sided t test.

**Reverse transcription-PCR and genotyping.** For reverse transcription-PCR analysis of EML4-ALK, we used primer sequences (primer set 1) as described in ref. 3. The forward primer is located at exon 13 of EML4, whereas the reverse primer is located at exon 20 of ALK. To detect other potential EML4-ALK fusion products, we designed a second forward primer from exon 3 of EML4 (5’-taccagtgctgcaatcaggg-3’) while using the same reverse primer as the primer set 1. PCR amplification was done using JumpStart Taq enzyme (Sigma) under the manufacturer’s guidelines. The resulting PCR products were analyzed using agarose gel electrophoresis. Genotyping for KRAS, epidermal growth factor receptor (EGFR), HER2, BRAF, and PIK3CA was done using either R.K. Thomas, C.H. Merem, D. Chiang, and M. Meyerson, unpublished results.
a reverse transcription-PCR based or a genomic DNA-based SURVEY-OR-WAVE mutation analysis (11) followed by sequencing of the positive specimens or by direct sequencing of the PCR products. Primer sequences and PCR conditions are available upon request.

Fluorescence in situ hybridization. Bacterial artificial chromosomes RP11-667I6 and RP11-100C1 (Children’s Hospital Oakland Research Institute) were used as probes for the EML4 and ALK genes, respectively. Bacterial artificial chromosome DNA was labeled with either spectrum red dUTP or spectrum green-11-dUTP by nick translation (Vysis) using manufacturer’s recommended conditions. Slides for metaphase fluorescence in situ hybridization (FISH) from cell lines were prepared using standard cytogenetic methodologies. Paraffin-embedded slides were prepared as described previously in ref. 11. Probes were hybridized and washed according to standard FISH procedures (12).

Kinase inhibitors. TAE684 was synthesized according to published procedures (13). The structure of TAE684 was confirmed using liquid chromatography-mass spectrometry and 1H and 13C nuclear magnetic resonance. The synthesized TAE684 was determined to be 98% pure by 1H nuclear magnetic resonance and 99% pure by liquid chromatography-mass spectrometry monitoring at 210 and 254 nm wavelengths (data not shown). CL-387,785 was purchased from Calbiochem. Erlotinib was purchased from the Dana-Farber Cancer Institute pharmacy. All drugs were dissolved in DMSO, stored at -70°C, and diluted in fresh medium before use.

Cell proliferation and growth assays. Growth inhibition was assessed by MTS assay as described in ref. 11. NSCLC cells were exposed to drugs alone or in combination for 72 h. All experimental points were set up in 6 to 12 wells and repeated at least three times. The data were graphically displayed using GraphPad Prism version 3.00 for Windows (GraphPad Software).14 The curves were fitted using a nonlinear regression model with a sigmoidal dose response.

Antibodies and Western blotting. Cells were lysed in buffer containing protease inhibitors, and proteins separated by gel electrophoresis on 5% to 12% polyvinylidene difluoride membranes, and detected by immunoblotting using an enhanced chemiluminescence system (Perkin-Elmer) as described previously (11). The receptor tyrosine kinase (RTK) array was purchased from R&D Systems and used according to the manufacturer’s recommended conditions. Anti-ALK, anti-phospho-ALK (Tyr1604), anti-phospho-Akt (Ser 473), anti-Akt, anti-STAT3, anti-phospho-STAT3 (Tyr705), anti-PTEN, and anti–poly(ADP-ribose) polymerase antibodies were obtained from Cell Signaling Technology. Total ERK1/2 and phospho-ERK1/2 (pT185/pY187) antibodies were purchased from Biosource International. The anti-α-tubulin antibody was purchased from Sigma-Aldrich.

14 http://www.graphpad.com
Fluorescence-activated cell sorting analysis. Cells were plated at a density of 0.5 to 2 × 10^5 per plate in 10 cm² plates. Drugs were added to the medium after 24 h, and the cells were incubated for another 72 h, after which the cells were analyzed as described previously (14). Percent apoptosis was estimated from the sub-G1 cell fraction.

Xenograft studies. Nude mice (nu/nu; 6-8 weeks old; Charles River Laboratories) were used for in vivo studies and were cared for in accordance with the standards of the Institutional Animal Care and Use Committee under a protocol approved by the Animal Care and Use Committee of the Beth Israel Deaconess Medical Center. Mice were anesthetized using a 2% isoflurane (Baxter) inhalation oxygen mixture. A suspension of 5 × 10^6 H3122 lung cancer cells (in 0.2 mL PBS) were inoculated s.c. into the lower right quadrant of the flank of each mouse. Mice were randomized to four treatment groups (n = 5 per group) once the mean tumor volume reached 500 to 600 mm³: vehicle (10% 1-methyl-2-pyrrolidinone/90% PEG-300) alone, erlotinib, and 10 and 25 mg/kg/d TAE684 orally (6). Erlotinib was administered at 100 mg/kg/d orally as described previously (11). Tumors were measured twice weekly using calipers, and volume was calculated using the formula: length × width^2 × 0.52. Mice were monitored daily for body weight and general condition. The experiment was terminated when the mean size of either the treated or control groups reached 2,000 mm³.

Results

**Identification of EML4-ALK fusion genes in NSCLC cell lines.** To rapidly screen our panel of 83 lung cancer cell lines (Supplementary Table S1) for potential ALK translocations, we used Affymetrix HuEx-1.0 mRNA exon arrays and focused on 104 unique probes covering the ALK gene. We identified two cell lines, H3122 and H2228, which had statistically significant (P < 0.001) breakpoints in the ALK gene (Fig. 1A; C, DFCI032 cell line). The EML4-ALK fusion signal (yellow; arrow) is detected in a small extrachromosomal fragment (yellow). Similar findings were observed for H3122 (data not shown). D, interphase FISH for EML4-ALK from the formalin-fixed paraffin-embedded tumor specimen obtained from the pleura of the patient whose pleural effusion was used to establish the DFCI032 cell line in C. The tumor is heterozygous for the EML4-ALK fusion signal (yellow dot; arrow).

**Table 1.** Frequency of the EML4-ALK fusion gene in NSCLC tumors and its association with clinical, pathologic, and genetic factors

<table>
<thead>
<tr>
<th>Clinical, pathologic, and genetic characteristics</th>
<th>EML4-ALK, n (%)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>All tumors</td>
<td>8 (3)</td>
<td>297 (97)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. cohort</td>
<td>2 (1)</td>
<td>136 (99)</td>
</tr>
<tr>
<td>Korean cohort</td>
<td>6 (3)</td>
<td>167 (97)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3 (2)</td>
<td>184 (98)</td>
</tr>
<tr>
<td>Female</td>
<td>5 (4)</td>
<td>119 (96)</td>
</tr>
<tr>
<td>Smoking (&lt;10 pack-years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>4 (6)</td>
<td>65 (27)</td>
</tr>
<tr>
<td>Smoker</td>
<td>2 (1)</td>
<td>182 (73)</td>
</tr>
<tr>
<td>Age, median (y)</td>
<td>55.9</td>
<td>61.9</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>4 (2)</td>
<td>179 (98)</td>
</tr>
<tr>
<td>II</td>
<td>1 (2)</td>
<td>58 (98)</td>
</tr>
<tr>
<td>III</td>
<td>3 (6)</td>
<td>47 (94)</td>
</tr>
<tr>
<td>IV</td>
<td>0 (0)</td>
<td>9 (100)</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>8 (4)</td>
<td>200 (96)</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>0 (0)</td>
<td>88 (100)</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>0 (0)</td>
<td>9 (100)</td>
</tr>
<tr>
<td>Oncogenic mutations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR</td>
<td>1 (1)</td>
<td>68 (99)</td>
</tr>
<tr>
<td>Kras</td>
<td>0 (0)</td>
<td>49 (100)</td>
</tr>
<tr>
<td>Braf</td>
<td>0 (0)</td>
<td>4 (100)</td>
</tr>
</tbody>
</table>

*Fisher’s exact test. NS, not statistically significant (P > 0.05).
Supplementary Fig. S1). Although our algorithm did not consider the location or direction of the breakpoint, the inferred ALK breakpoints in both samples were very near the conserved exon 20 breakpoint in the ALK gene, and in both samples, the expression was higher in the 3' than the 5' ends. Using reverse transcription-PCR, we were able to confirm the presence of the EML4-ALK fusion gene product in both H3122 and H2228 but not in any other of the 81 cell lines. In H3122, we detected variant 1 of EML4-ALK (Fig. 1B and C). In H2228, we detected a novel variant (named variant 3a hereafter) resulting from a fusion of exon 6 (codons 1-222) of EML4 with exon 20 (codons 1,058-1,621) of ALK (Fig. 1C; Supplementary Fig. S2). A second fusion gene (variant 3b) was also detected from this cell line and contains an additional 33-bp fragment derived from an alternatively spliced exon of EML4 (exon 6b; Fig. 1C; Supplementary Fig. S2) and is the predominant form in H2228 (data not shown). This alternatively spliced exon was not detected in any of the other fusion variants. As both H3122 and H2228 cell lines were established from female NSCLC patients with adenocarcinoma and H2228 is from a never-smoker, we screened for the presence of EML4-ALK in NSCLC cell lines with these clinical features that we have established at Dana-Farber Cancer Institute. We identified two cell lines, DFCI024 and DFCI032, both derived from chemotherapy naive female never-smokers with adenocarcinoma. Both cell lines are wild-type for EGFR and KRAS. We detected variant 1 of the EML4-ALK fusion gene in the DFCI032 cell line and neither variant in DFCI024 (Fig. 1B). Overall, we detected the EML4-ALK fusion gene in 3 of 83 (3.6%) NSCLC cell lines. We further confirmed the presence of

**Fig. 3.** Effect of TAE684 on growth and signaling in EML4-ALK-containing NSCLC cell lines. A, NSCLC cells were treated with TAE-684 at the indicated concentrations, and viable cells were measured after 72 h of treatment. The percentage of viable cells is shown relative to untreated controls. A549 (KRAS G12S), PC-9 (EGFR del E746_A750), H2228 (EML4-ALK variant 3), H3122 (EML4-ALK variant 1), and DFCI032 (EML4-ALK variant 1). B, fluorescence-activated cell sorting analysis of sub-G1 fraction without treatment (left column) and after treatment with 0.1 μmol/L TAE684 for 72 h (right column). Significant apoptosis following TAE-684 treatment is only observed in the H3122 cell line. C, Western analysis of poly(ADP-ribose) polymerase following treatment with 0.1 μmol/L TAE684 for 72 h. The 89-kDa cleaved poly(ADP-ribose) polymerase products is observed only in the H3122 cell line consistent with the effects of TAE-684 on cell growth in A. D, Western analysis following TAE684 treatment in wild-type and EML4-ALK-positive NSCLC cell lines. Total and phosphorylated ALK are only detected in EML4-ALK-positive cell lines (H3122, H2228, and DFCI032) but not in wild-type control (PC-9). In H3122 and DFCI032 cell lines, ALK-positive band migrates at ~120 kDa corresponding to predicted molecular weight (117 kDa) of the variant 1 (arrow 1), whereas in H2228 the band migrates at ~90 kDa, which also corresponds to the predicted molecular weight (90/91 kDa) of the variant 3 (arrow 3). ALK phosphorylation is completely inhibited following 0.1 μmol/L TAE684 treatment (6 h) in all the cell lines. Phosphorylation of Akt, STAT3, and ERK1/2 decreases in H3122 and H2228 cell lines with TAE684 but remain unchanged in DFCI032 and PC-9 lines. All the cell lines show presence of PTEN. α-Tubulin is used as a loading control.
the EML4-ALK inversion using FISH (Supplementary Fig. S3) in these three cell lines (Fig. 2A-C). In addition, we confirmed the presence of the EML4-ALK fusion in the original tumor specimen that gave rise to the DFCI032 cell line using interphase FISH (Fig. 2D).

**EML4-ALK fusion gene is detected in both Caucasian and Asian NSCLC.** We screened NSCLC (n = 305) from patients of U.S. (n = 138) and Korean (n = 167) origin for the EML4-ALK fusion gene and detected its presence in 8 of 305 (3%) NSCLC (Table 1). Four tumors contained variant 3 (both variants 3a and 3b, with 3b being predominant), two contained variant 1, and two contained a novel variant (named variant 4 hereafter; Fig. 1B and C). In variant 4, exon 15 of EML4 is fused with exon 20 of ALK (EML4 exons 1-569 to 1,078-1,621 of ALK; Fig. 1C; Supplementary Fig. S2). Six of the EML4-ALK-containing tumors (6 of 167; 3.6%) were from Korean patients, whereas 2 of 138 (1.5%) were detected in NSCLC from U.S. patients. The frequency of EML4-ALK was higher in females (4%) versus males (2%). All eight of the EML4-ALK-containing tumors were adenocarcinomas. Furthermore, the fusion gene was detected significantly (P = 0.049; Table 1) more frequently in patients (6%; 4 of 69) with limited smoking history (<10 pack-years) compared with tumors from smokers (1%; 2 of 184). The tumor from one of the patients had a concurrent EGFR kinase domain mutation (del E746_A750) with the EML4-ALK fusion gene. None of the eight tumors contained a concurrent KRAS or BRAF mutation (data not shown).

**Inhibition of ALK kinase activity in EML4-ALK fusion gene in vitro and in vivo.** To determine whether ALK kinase inhibitors may be therapeutically effective in EML4-ALK-containing NSCLC, we evaluated TAE684, a highly potent ALK kinase inhibitor (6). We found that TAE684 significantly inhibited the growth of only the H3122 cell line, whereas the other two EML4-ALK-containing cell lines, H2228 and DFCI032, were as resistant (IC50 >10 μmol/L) to the inhibitor as those containing an EGFR mutation (PC-9; del E746_A750) or a KRAS mutation (A549; G12S; Fig. 3A and D). It should be noted that the IC50 for the H3122 cells is 10 nmol/L and that TAE684 exhibits its maximal effects in this responsive cell line at 100 nmol/L (Fig. 3A). At these low concentrations, TAE684 is highly selective for ALK; therefore, the observed response is not likely to be due to off-target effects (6). Conversely, the effects on the EGFRTK mutant PC-9 and KRAS mutant A549 cells, which are not ALK dependent for their growth, at concentrations >1 μmol/L are likely to be due to off-target effects; thus, we used 100 nmol/L TAE684 for subsequent studies. TAE684 (100 nmol/L) treatment led to significant apoptosis only in the H3122 cell line as detected by fluorescence-activated cell sorting (Fig. 3B) or by Western blotting for cleaved poly(ADP-ribose) polymerase (Fig. 3C). No growth arrest or apoptosis was observed in the other cell lines following TAE684 treatment.

To determine why the growth of only one of three of the EML4-ALK-containing cell lines was inhibited by TAE684, we examined its effects on phosphorylation of ALK and downstream signaling proteins (Fig. 3D). Following 100 nmol/L TAE684 treatment, complete inhibition of phosphorylated ALK was observed in all three of the EML4-ALK-positive cell lines (Fig. 3D). However, this was accompanied by substantial inhibition of Akt as well as ERK1/2 phosphorylation only in the H3122 cell line consistent with the effects on cell growth and apoptosis in this cell line (Fig. 3A-C). In contrast to Akt and ERK1/2, there was only a minimal decrease in STAT3 phosphorylation following TAE684 treatment in the H3122 cell line (Fig. 3D). In the H2228 cell line, there was some but not complete inhibition of Akt and ERK1/2 phosphorylation, whereas these were unchanged in the DFCI032 cell line (Fig. 3D).

We also examined the effects of TAE684 treatment on H3122 in vitro. Using a xenograft model, we compared the effects of TAE684 with the EGFR kinase inhibitor erlotinib, which did not inhibit the growth of H3122 cells in vitro (IC50 >10 μmol/L; data not shown). We used erlotinib because we detected EML4-ALK significantly more frequently in never or former light cigarette smokers with NSCLC (Table 1) and because erlotinib is frequently used in clinical trials in this same patient population (11, 15). Thus, we wished to determine the efficacy of erlotinib in EML4-ALK-containing NSCLC. We also explored the dosing of TAE684 by examining two different doses in the xenograft studies. As can be seen in Fig. 4, both doses of TAE684 effectively inhibited the growth of H3122 xenografts. Both vehicle-treated and erlotinib-treated mice were all sacrificed following 2 weeks of treatment due to rapid tumor growth. These are consistent with the effects of erlotinib in vitro (data not shown). The higher dose of TAE-684 (25 mg/kg/d) more effectively inhibited tumor growth than the lower (10 mg/kg/d) dose (Fig. 4). The 25 mg/kg/d dose was associated with an initial shrinkage of established tumors followed by stabilization. All mice were sacrificed at day 53 of treatment.

**Coactivation of ERBB family members in an EML4-ALK-containing NSCLC.** In the DFCI032 cell line, which contains the exact same EML4-ALK variant as H3122 (Fig. 1B), TAE684 completely inhibited ALK phosphorylation, but this was not accompanied by inhibition of growth or changes in phosphorylation of Akt or ERK1/2 (Fig. 3A and D). DFCI032 is not a heterogeneous cell line as by FISH we were able to detect EML4-ALK in 100% of the cells (data not shown). We also did not detect a concurrent mutation in the known oncogenes (EGFR, KRAS, BRAF, HER2, or PIK3CA) commonly mutated in NSCLC.
in the DFCI032 cell line (data not shown). Recent studies have shown that in some cancers multiple RTK can be coactivated (11, 16). Inhibition of only one of the coactivated kinases is insufficient to result in inhibition of growth or Akt phosphorylation (11, 16). To determine whether DFCI032 contained other activated kinases, we performed a screen using a phospho-RTK array comprising 42 RTK. As can be seen in Fig. 5A, the two most intense signals detected in this array were for phosphorylated EGFR and ERBB2. Low-level activation of other RTK were also observed, but the signals were substantially weaker than for EGFR and ERBB2 (Fig. 5A). ALK is not present on this array (data not shown). We next examined the effects of CL-387,785 (1 μmol/L), an irreversible EGFR and ERBB2 inhibitor, alone or in combination with TAE684 (100 nmol/L) in the DFCI032 cell line. The combination of CL-387,785 and TAE684, but not either agent alone, significantly inhibited the growth of DFCI032 cells and was associated with significant apoptosis (Fig. 5C and D). Furthermore, only the combination of TAE684 and CL-387,785 was associated inhibition of Akt and ERK1/2 phosphorylation (Fig. 5D). We also examined the combination of the EGFR inhibitor gefitinib (1 μmol/L) and TAE684 (100 nmol/L) and observed no effect on growth of DFCI032 cells (data not shown). These findings suggest that inhibition of both EGFR and ERBB2 along with ALK is necessary to effectively inhibit growth and induce apoptosis in the DFCI032 cell line.

Discussion

The use of molecular targeted therapy in genetically defined subsets of cancer patients is emerging as an effective therapeutic strategy for many cancers (17–19). In lung cancer, for example, 10% to 30% of NSCLC contain activating mutations in the EGFR kinase domain and 60% to 80% of the patients with EGFR mutations obtain dramatic radiographic responses following treatment with the EGFR kinase inhibitors gefitinib or erlotinib (11, 19). Similarly, EGFR mutant NSCLC cell lines are exquisitely sensitive to gefitinib in vitro compared with wild-type NSCLC cell lines and only EGFR mutant NSCLC cell lines undergo apoptosis following gefitinib treatment (14, 20, 21). Thus, it remains critical to identify subsets of lung cancer patients and to develop effective therapeutic strategies for such patients. As lung cancer is a very common cancer, the identification of even small subsets of lung cancer patients harboring specific genetic alterations will translate into a large cohort of patients.

In the present study, we characterized the frequency of the EML4–ALK fusion gene in NSCLC cell lines and primary tumors from NSCLC patients of different ethnic backgrounds. We detected the EML4–ALK fusion gene in 3% of NSCLC specimens, numerically more frequently from Korean than U.S. NSCLC patients, adenocarcinomas, and in patients with limited cigarette smoke exposure. Our study is the first example addressing the frequency of EML4–ALK in Caucasian NSCLC patients. Despite the low frequency of EML4–ALK in NSCLC, this represents more patients (~5,000 annually in United States) than those diagnosed with anaplastic large cell lymphoma where ALK translocations have been detected previously (22, 23). We detected EML4–ALK significantly more frequently (Table 1) from NSCLC patients who were either never or former light (≤10 pack-years) cigarette smokers. This same clinical feature has also been shown to predict for presence of EGFR mutations (24). Thus, it is possible that NSCLC arising in never/former light smokers are genetically and biologically different from those arising in smokers and more likely to contain activated oncogenes. We detected four different variants of EML4–ALK (Fig. 1) containing virtually identical portions of ALK, comprising the entire kinase domain, with varying portions of EML4. These variants are similar to previously described translocations of ALK with other genes; all of which contain the cytoplasmic portion and entire tyrosine kinase domain of ALK (22). We also developed a FISH assay, which can be used to detect the EML4–ALK inversion from routine paraffin-embedded lung cancer clinical specimens. This will facilitate the identification of appropriate NSCLC patients for clinical studies of ALK kinase inhibitors.

One of the three cell lines with the EML4–ALK translocation (H3122) was also found to be exquisitely sensitive to TAE684 in vitro and in vivo (Figs. 3A and 4). In addition, TAE684 treatment was associated with significant apoptosis and down-regulation of Akt and ERK1/2 signaling (Fig. 3B-D). These findings suggest the phenomenon of oncogene addiction where ALK kinase solely controls the critical survival signaling pathways in this cell line (25). ALK inhibition leads to inhibition of all of these signaling pathways and subsequently to apoptosis. This is analogous to gefitinib treatment of EGFR mutant NSCLC and suggests that ALK kinase inhibitors alone may be effective therapies at least for some patients whose tumors contain EML4–ALK (14, 26). Interestingly, TAE-684 led to only a minimal decrease in STAT3 phosphorylation in H3122 despite causing apoptosis in this cell line (Fig. 3D). STAT3 has been shown to be critical to NPM-ALK-mediated lymphomagenesis and inhibition of STAT3 alone using a dominant-negative STAT3 is sufficient to induce apoptosis (27, 28). There may be signaling differences between NPM-ALK-containing and EML4–ALK-containing tumors or this may reflect differences between NSCLC and anaplastic large cell lymphoma. Further studies will be are necessary to determine the significance of STAT3 signaling in EML4–ALK-containing NSCLC.

Only one of three NSCLC cell lines (H3122) with EML4–ALK was sensitive to the ALK kinase inhibitor alone. The two other EML4–ALK-containing cell lines were either resistant to TAE684 alone (H2228) or required concomitant inhibition of EGFR and ERBB2 (DFCI032). These findings are quite different from EGFR mutant NSCLC cell lines where the majoritly are exquisitely sensitive to gefitinib or erlotinib in vitro and the growth inhibition is accompanied by apoptosis and significant inhibition of EGFR, ERK1/2, and Akt phosphorylation (14, 29, 30). These differences may be clinically significant and highlight the possibility that ALK inhibitors alone may only be effective in a subset of NSCLC patients with the EML4–ALK inversion. Our studies of DFCI032 suggest that it contains coactivation of both EGFR and ERBB2 as concomitant inhibition of ALK, EGFR, and ERBB2 is required to significantly effect growth, induce apoptosis, and inhibit Akt and ERK1/2 phosphorylation (Fig. 5). Thus, our findings provide one potential mechanism, activation of other RTK, by which resistance could emerge in NSCLC patients being treated with ALK inhibitors. In addition, these data suggest that, in some EML4–ALK-containing NSCLC, a combination therapeutic strategy may be necessary. Our findings are analogous to those
found in subsets of glioblastoma multiforme and in MET-amplified gefitinib-resistant lung cancers where multiple kinases are coactivated and inhibition of one kinase alone is not sufficient to effect growth or lead to down-regulation of Akt (11, 16). In H2228, we did not detect coactivation of another kinase (data not shown). The lack of efficacy of TAE684 in our study in H2228 is similar with recent studies using an ALK-specific small interfering RNA, which also did not inhibit the

Fig. 5. Coactivation of EGFR and ERBB2 in DFCI032 cell line. A, a phospho-RTK array reveals that the DFCI032 cells contain strong activation of both EGFR and ERBB2. Cells were grown in medium and the cell lysates were hybridized to a phospho-RTK array. In the array, each RTK is spotted in duplicate. Hybridization signals at the corners serve as controls. B, combination of TAE684 and CL-387,785 effectively inhibits growth of DFCI032 cells. DFCI032 cells were treated with either CL-387,785 (1 μmol/L) alone, TAE684 (100 nmol/L) alone, or the two in combination for 72 h. Growth was assayed by MTS (see Materials and Methods). The combination of TAE684 and CL-387,785 led to significant inhibition of growth compared with untreated (P < 0.001, paired t test) or treatment with either agent alone (P < 0.001, paired t test for both comparisons, respectively). **, P < 0.001. C, combination of CL-387,785 and TAE-684 leads to significant apoptosis. Cells were treated as in B and apoptosis was estimated from sub-G1 fraction using fluorescence-activated cell sorting (Materials and Methods). The combination of CL-387,785 and TAE-684 led to significant increase in apoptosis compared with untreated (P < 0.05, paired t test) or treatment with either agent alone (P < 0.05, paired t test for both comparisons, respectively). *, P < 0.05. D, combination of CL-387,785 and TAE-684 leads to inhibition of Akt and ERK1/2 phosphorylation. Cells were treated as in B for 6 or 48 h. Cells were lysed and the indicated proteins were detected by immunoblotting. Only the combination of CL-387,785 and TAE-684 led to significant down-regulation of Akt and ERK1/2 signaling and to apoptosis as measured by appearance of cleaved (89 kDa) poly(ADP-ribose) polymerase fragment.
growth of H2228 cells (31). It will continue to be important to study H2228 and other EML4-ALK-containing tumors to determine whether an ALK inhibitor alone or in combination with other kinase inhibitors will be necessary for growth inhibition and apoptosis.

References

Disclosure of Potential Conflicts of Interest
J. Engelman (member of Hoffman-LaRoche advisory board) and N. Gray (former Novartis employee) received research grant from Novartis and M. Meyerson received a research grant from Novartis and consults for Novartis. The other authors disclosed no potential conflicts of interest.
Clinical Cancer Research

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi P. Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/14/13/4275

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2008/09/03/14.13.4275.DC1

Cited articles
This article cites 30 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/14/13/4275.full.html#ref-list-1

Citing articles
This article has been cited by 91 HighWire-hosted articles. Access the articles at:
/content/14/13/4275.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.